Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114058 | 0.83 | CYP3A4 (0.56) | CYP3A4TRPV1 | |
| SCHEMBL2111743 | 0.80 | CYP3A4 (0.39) | CYP3A4TRPV1NR3C2HDAC1EPHX2 | |
| SCHEMBL2912906 | 0.80 | CYP3A4 (0.39) | CYP3A4TRPV1NR3C2HDAC1EPHX2 | |
| SCHEMBL2111740 | 0.80 | CYP3A4 (0.39) | CYP3A4TRPV1NR3C2HDAC1EPHX2 | |
| SCHEMBL1530141 | 0.76 | TRPV1 (0.42) | CYP3A4TRPV1NR3C2HDAC1PIP4K2A | |
| SCHEMBL1530139 | 0.76 | TRPV1 (0.42) | CYP3A4TRPV1NR3C2HDAC1PIP4K2A | |
| SCHEMBL12203178 | 0.74 | CYP3A4 (0.38) | CYP3A4TRPV1NR3C2HDAC1EPHX2 | |
| SCHEMBL1348091 | 0.71 | CYP3A4 (0.48) | CYP3A4TRPV1NR3C2HDAC1PIP4K2A | |
| SCHEMBL1348089 | 0.71 | CYP3A4 (0.48) | CYP3A4TRPV1NR3C2HDAC1PIP4K2A | |
| SCHEMBL2112556 | 0.70 | CYP3A4 (0.56) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445875-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | claimed |
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-12-30 | — | — | US | claimed |
| WO-2010149598-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | claimed |
| EP-2445875-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-8158631-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-12-30 | — | — | US | disclosed |
| WO-2010149598-A2 | HETEROCYCLIC ANTIVIRAL COMPOUND | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | CYP3A4 305/4885TRPV1 4388/4885NR3C2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.